Optical coherence tomography as a potential readout in clinical trials

Area of Science:

• Ophthalmology
• Neurology
• Biomedical Imaging

Background:

• Optical coherence tomography (OCT) is a noninvasive imaging technique for micrometer-resolution tissue measurement.
• OCT is increasingly explored as a biomarker for neurologic conditions, leveraging the retina's direct connection to the central nervous system.
• Current imaging modalities for quantifying axonal degradation in neurologic diseases lack sensitivity and specificity.

Purpose of the Study:

• To evaluate the potential of OCT as a noninvasive surrogate marker for neurodegeneration.
• To explore OCT's utility in measuring the efficacy of neuroprotective agents in clinical trials.
• To document the natural history of neurodegeneration in conditions like Alzheimer's, Parkinson's, and multiple sclerosis using OCT.

Main Methods:

• Utilizing OCT to measure changes in the retinal nerve fiber layer.
• Correlating retinal changes with established neurodegenerative disease progression.
• Assessing the reproducibility and sensitivity of OCT for detecting axonal degeneration.

Main Results:

• Early data indicate pathologic changes in the retinal nerve fiber layer in several neurologic conditions.
• OCT demonstrates potential as a noninvasive and reproducible test for axonal degeneration.
• OCT can potentially serve as a biomarker for neurodegeneration, aiding in treatment assessment.

Conclusions:

• OCT is a promising technology for noninvasive assessment of neurodegeneration.
• OCT can be a valuable tool for measuring treatment efficacy in neuroprotection trials.
• Documenting neurodegeneration via OCT may accelerate the development of therapies for neurologic diseases.